Overview


According to FutureWise analysis the market for Guillain-Barre Syndrome in 2023 is US$ 0.41 billion, and is expected to reach US$ 0.63 billion by 2031 at a CAGR of 5.42%.

One of the most common risk factors for developing Guillain-Barre syndrome is infection with the bacteria Campylobacter jejuni. After catching the flu or contracting the Cytomegalovirus or Epstein–Barr virus, the condition can emerge. Guillain-Barre syndrome can appear days or weeks after a vaccine. The senior population is at a higher risk of getting Guillain-Barre syndrome (GBS), according to the Centers for Disease Control and Prevention, because the condition's incidence rises with age. People over the age of 50 are at the greatest risk of contracting GBS. Guillain-Barre Syndrome is a rare neurological illness in which the body's immune system attacks the nervous system, which consists of a network of nerves outside the brain and spinal cord. Guillain-Barre Syndrome can range in severity from a minor weakening to a near-complete paralysis. Weakness and tingling in the extremities are frequently the first indications and symptoms. Around 80% of persons with Guillain-Barre can walk freely after six months, and 60% can regain their normal muscle strength after a year. After three years, about 30% of people still have some weakness. For the treatment of Guillain–Barré syndrome, intravenous immunoglobulins are used. Gamunex, Gammagard/Kiovig, and Privigen are IVIG medicines that are given at a dose of 0.4 g/kg of body weight every day for five days.

Guillain–Barre syndrome can be treated by plasma exchange. Other medications, such as analgesics, anticonvulsants, and low-molecular-weight heparin, are used to treat Guillain–Barré syndrome symptoms and consequences. Intravenous and subcutaneous modes of administration are used to give immunoglobulins. The intravenous method of administration is used to deliver albumin for plasma exchange in individuals with Guillain–Barré syndrome. Hospital pharmacies provide all medications for patients, as well as surgical supplies, speciality care goods, pathological supplies, and a 24-hour service. The Guillain–Barré syndrome market's primary distribution channel is hospital pharmacies.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Guillain-Barre Syndrome Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Guillain-Barre Syndrome Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Kedrion s.p.A
  • Nihon Pharmaceutical Co., Ltd.
  • CSL Behring LLC
  • Shire plc
  • Akari Therapeutics, PLC
  • Biotest AG
  • China Biologic Products Holdings, Inc
  • Grifols S.A
  • Natus Medical Inc
  • Covidien Ltd
  • Octapharma AG
  • Baxter

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
  • Miller Fisher Syndrome (MFS)
  • Acute Motor Axonal Neuropathy (AMAN)
  • Acute Motor-Sensory Axonal Neuropathy (AMSAN)
  • Others

By Diagnosis

  • Spinal Tap (Lumbar Puncture)
  • Electromyography
  • Nerve Conduction Studies
  • Others

By Treatment

  • Plasma Exchange (Plasmapheresis)
  • Immunoglobulin Therapy
  • Others

By Distribution Channel

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Guillain-Barre Syndrome Market By Type, By Diagnosis, By Treatment, By Distribution Channel, By End-Users and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Guillain-Barre Syndrome Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Guillain-Barre Syndrome Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Guillain-Barre Syndrome Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Guillain-Barre Syndrome Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
        2. Miller Fisher Syndrome (MFS)
        3. Acute Motor Axonal Neuropathy (AMAN)
        4. Acute Motor-Sensory Axonal Neuropathy (AMSAN)
        5. Others

  • 8.   Guillain-Barre Syndrome Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Spinal Tap (Lumbar Puncture)
        2. Electromyography
        3. Nerve Conduction Studies
        4. Others

  • 9.   Guillain-Barre Syndrome Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Plasma Exchange (Plasmapheresis)
        2. Immunoglobulin Therapy
        3. Others

  • 10.   Guillain-Barre Syndrome Market, By Distribution Channels Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Direct Tender
        2. Hospital Pharmacy
        3. Retail Pharmacy
        4. Online Pharmacy
        5. Others

  • 11.   Guillain-Barre Syndrome Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Home Healthcare
        4. Others

  • 12.   North America Guillain-Barre Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Guillain-Barre Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Guillain-Barre Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Guillain-Barre Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Guillain-Barre Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •     1. Kedrion s.p.A
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Nihon Pharmaceutical Co., Ltd.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. CSL Behring LLC
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Shire plc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Akari Therapeutics, PLC
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Biotest AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. China Biologic Products Holdings, Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Grifols S.A
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Natus Medical Inc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Covidien Ltd
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Octapharma AG
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Baxter
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients